Warp Sciences Raises $215 Million to Automate Drug Discovery Labs

Oct 22, 2026
Former OpenAI science lead Kevin Weil launched Warp Sciences with $215 million in funding at an $865 million valuation. The startup will train robots to make and test compounds for drug discovery.

Warp Sciences, founded by former OpenAI science lead Kevin Weil, has raised $215 million at an $865 million valuation, Weil announced on X, TechCrunch reports. The company will use robots to make and test compounds identified by drug researchers.

Lightspeed Venture Partners led the funding round, with participation from IVP, Premji Invest, and Lux Capital.

Human chemists wearing cameras and sensor gloves will train the robots to perform wet lab tasks. Warp Sciences plans to automate work that biotech companies often outsource to contractors in China, allowing lab operations to continue around the clock.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like AI Funding Brief, Robotics Brief or Daily AI Brief.

Also, consider following us on social media:

AI Funding News AI & Robotics AI Brief AI Brief (X)
Free newsletter

Robotics Brief

Weekly coverage of AI-driven robotics advances in industrial automation, autonomous vehicles, and robotic systems.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.